glp-1 medication semaglutide vs. Other Receptor Agonists GLP-1 Therapy for Obesity Requires

Wegovy is approved for weight management in adults and children 12 and older who have obesity or are overweight with a related health issue such as high blood pressure or high cholesterol

Clinical trials have not identified hepatotoxicity as a characteristic adverse effect of semaglutide, though rare idiosyncratic reactions cannot be completely excluded

This product has NOT been evaluated or approved by the MHRA

The FDA declared the semaglutide shortage resolved in February 2025, with 503A compounding winding down around April 22, 2025 and 503B around May 22, 2025

Glutathione and NAC both act as powerful antioxidants

The National Institutes of Health (NIH) explains, GLP-1 (Glucagon-Like Peptide-1) is a hormone that regulates blood sugar and appetite by triggering insulin release and slowing digestion, creating lasting fullness. 1 GLP-1 receptors are present throughout the body, including the brain, GI tract, and pancreas